294 related articles for article (PubMed ID: 15471553)
1. The critical role of type-1 innate and acquired immunity in tumor immunotherapy.
Ikeda H; Chamoto K; Tsuji T; Suzuki Y; Wakita D; Takeshima T; Nishimura T
Cancer Sci; 2004 Sep; 95(9):697-703. PubMed ID: 15471553
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
3. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
4. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
5. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
6. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity.
Mashino K; Sadanaga N; Tanaka F; Ohta M; Yamaguchi H; Mori M
Mol Cancer Ther; 2002 Aug; 1(10):785-94. PubMed ID: 12492111
[TBL] [Abstract][Full Text] [Related]
7. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
8. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
9. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
10. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
14. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor.
Shi M; Su L; Hao S; Guo X; Xiang J
Tumori; 2005; 91(6):531-8. PubMed ID: 16457153
[TBL] [Abstract][Full Text] [Related]
15. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity.
Shirota H; Klinman DM
Cancer Immunol Immunother; 2011 May; 60(5):659-69. PubMed ID: 21318638
[TBL] [Abstract][Full Text] [Related]
16. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities.
Massa C; Seliger B
J Immunol; 2013 Apr; 190(7):3328-37. PubMed ID: 23447683
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
19. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
[TBL] [Abstract][Full Text] [Related]
20. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
